{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:16:46Z","timestamp":1788873406209,"version":"build-2803163510"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T00:00:00Z","timestamp":1421712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10238-015-0337-6","type":"journal-article","created":{"date-parts":[[2015,1,19]],"date-time":"2015-01-19T11:54:35Z","timestamp":1421668475000},"page":"99-101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Paralytic ileus following \u201csubcutaneous bortezomib\u201d therapy: focus on the clinical emergency\u2014report of two cases"],"prefix":"10.1007","volume":"16","author":[{"given":"Giuseppe","family":"Mele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Coppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Melpignano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,20]]},"reference":[{"key":"337_CR1","first-page":"2297","volume":"31","author":"T Fukushima","year":"2011","unstructured":"Fukushima T, Nakamura T, Iwao H, et al. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res. 2011;31:2297\u2013302.","journal-title":"Anticancer Res"},{"issue":"34","key":"337_CR2","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Rossi D, et al. Bortezomib\u2013melphalan\u2013prednisone\u2013thalidomide followed by maintenance with bortezomib\u2013thalidomide compared with bortezomib\u2013melphalan\u2013prednisone for initial treatment of multiple myeloma: a randomized controlled trial. JCO. 2010;28(34):5101\u20139.","journal-title":"JCO"},{"issue":"9","key":"337_CR3","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva N, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Eng J Med. 2008;359(9):906\u201317.","journal-title":"N Eng J Med"},{"key":"337_CR4","first-page":"431","volume":"12","author":"F Moreau","year":"2011","unstructured":"Moreau F, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Oncology. 2011;12:431\u201340.","journal-title":"Oncology"},{"key":"337_CR5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/CMAR.S44261","volume":"6","author":"AA Argyriou","year":"2014","unstructured":"Argyriou AA, Kyritsis AP, Makatsoris T, et al. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014;6:135\u201347.","journal-title":"Cancer Manag Res"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-015-0337-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-015-0337-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-015-0337-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T11:37:41Z","timestamp":1559129861000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-015-0337-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,20]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1007\/s10238-015-0337-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,20]]}}}